Exhibit 99.1 Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates – Company continues to evaluate strategic options to maximize shareholder value - Watertown, Mass., March 27, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of can ...